Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer
04. November 2024 07:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren /...
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients
01. November 2024 07:00 ET
|
Memo Therapeutics AG
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections...
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
27. August 2024 07:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
27. August 2024 02:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...
Memo Therapeutics AG appoints Paul Carter as Chairperson
08. Juli 2024 07:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public...
Memo Therapeutics AG appoints Paul Carter as Chairperson
08. Juli 2024 02:00 ET
|
Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and...